

We Claim:

1. A synergistic combination comprising an antibody specific for CD19 wherein said antibody comprises an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RSSKSLQNVNGNTYLY (SEQ ID NO: 4), an LCDR2 region of sequence RMSNLNS (SEQ ID NO: 5), and an LCDR3 region of sequence MQHLEYPIT (SEQ ID NO: 6) and Idelalisib for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.

2. The combination according to claim 1, wherein the antibody comprises a variable heavy chain of the sequence EVQLVESGGGLVKPGGSLKLSAASGYTFTSYVMHWVRQAPGKGLEWIGYINPYNDGTYNEKFQGRVTISSDKSISTAYMELSSLRSEDAMYYCARGTYYYGTRVFDYWG QGTLTVSS (SEQ ID NO: 10) and a variable light chain of the sequence DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQLLIYRMSNLNSGVPDRFSGSGSGTEFTLTSSLEPEDFAVYYCMQHLEYPITFGAGTKLEIK (SEQ ID NO: 11).

3. The combination according to any one of the preceding claims, wherein the antibody comprises a heavy chain constant domain of the sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKALPAAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPMLDSGGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 12).

4. The combination according to any one of the preceding claims, wherein the antibody comprises a light chain constant domain of the sequence RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 13).

5. The combination according to any one of the preceding claims, wherein said antibody specific for CD19 and Idelalisib are administered separately.
6. The combination according to claim 5, wherein said antibody specific for CD19 and Idelalisib are administered separately physically.
7. The combination according to claim 5, wherein said antibody specific for CD19 and Idelalisib are administered separately in time.
8. The combination according to any one of claims 1-4, wherein said antibody specific for CD19 and Idelalisib are administered together.
9. The combination according to any one of the preceding claims, wherein Idelalisib is administered prior to administration of the antibody specific for CD19.
10. The combination according to any one of the preceding claims, wherein Idelalisib is administered after administration of the antibody specific for CD19.
11. The combination according to any one of claims 1-4, wherein Idelalisib and the antibody specific for CD19 are administered simultaneously.
12. The combination according to any one of the preceding claims for use in the treatment of non-Hodgkin's lymphoma, wherein the non-Hodgkin's lymphoma is selected from the group consisting of follicular lymphoma, small lymphocytic lymphoma, mucosa-associated lymphoid tissue, marginal zone, diffuse large B cell, Burkitt's, and mantle cell.
13. The combination according to any one of the preceding claims for use in the treatment of chronic lymphocytic leukemia.

14. The combination according to any one of the preceding claims for use in the treatment of acute lymphoblastic leukemia.